Skip to main content
Premium Trial:

Request an Annual Quote

CTC Technology Firm Clearbridge Raises $7.2M

NEW YORK (GenomeWeb News) – Singapore cancer diagnostics firm Clearbridge BioMedics announced on Wednesday the closing of a Series B financing round, bringing in S$9.0 million (US$7.2 million).

The financing will be used to further develop Clearbridge's ClearCell System, a non-biomarker-based platform for detecting, isolating, and retrieving circulating tumor cells from blood. The system consists of the ClearCell unit and single-use microfluidic biochips called CTChips.

The platform was launched in 2011 for the cancer research market, and Clearbridge intends to build out the technology for further applications, which will involve developing a next-generation system for improved accuracy, sensitivity, and reliability, according to Johnson Chen, managing director and co-founder of Clearbridge.

"It is a very exciting time for us and we plan to embark upon validation trials later this year to show the applicability of the ClearCell System in a clinical setting," he said in a statement.

The Series B round was led by Vertex Venture Holdings, the wholly owned venture capital arm of Temasek Holdings. Also participating were Spring Seeds Capital, Clearbridge BSA and Lu Yoh Chie, and existing shareholder BioVeda.

Clearbridge added that Chua Joo Hock, managing director and chief investment officer of Vertex is joining the board of the company, as is Lu, the founder of Biosensors International, who is being appointed chairman.

Clearbridge was spun out of the National University of Singapore in 2009 and is ISO13485 certified for developing cell-based in vitro diagnostic devices.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.